Small molecule · developed by Processa Pharmaceuticals
HT-100 is halofuginone hydrobromide in a delayed-release tablet formulation. It is studied in Duchenne muscular dystrophy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01847573 | Phase 1/2 | Duchenne Muscular Dystrophy | Terminated | PCSA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Duchenne Muscular Dystrophy
Updated Oct 25, 2026. Something wrong or missing? Report it on the PCSA page.
See PCSA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PCSA catalysts and pipeline →